Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Free Cash Flow (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Free Cash Flow for 16 consecutive years, with -$29.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 1353.42% to -$29.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$110.4 million through Dec 2025, down 579.76% year-over-year, with the annual reading at -$110.4 million for FY2025, 579.76% down from the prior year.
  • Free Cash Flow hit -$29.5 million in Q4 2025 for Vanda Pharmaceuticals, up from -$31.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $31.8 million in Q1 2023 to a low of -$33.6 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$965100.0 across 5 years, with a median of $970000.0 in 2022.
  • Biggest five-year swings in Free Cash Flow: soared 808.05% in 2021 and later crashed 1353.42% in 2025.
  • Year by year, Free Cash Flow stood at $26.5 million in 2021, then tumbled by 65.43% to $9.2 million in 2022, then plummeted by 143.54% to -$4.0 million in 2023, then skyrocketed by 49.03% to -$2.0 million in 2024, then plummeted by 1353.42% to -$29.5 million in 2025.
  • Business Quant data shows Free Cash Flow for VNDA at -$29.5 million in Q4 2025, -$31.8 million in Q3 2025, and -$15.6 million in Q2 2025.